Study wrapper · #897
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
Lee HM, Marakkalage KG, Kim SH, et al. International journal of obesity (2005). 2026.
DOI: 10.1038/s41366-026-02161-9PubMed: 42457940
Editor's note
This is a mouse study whose primary subject is vutiglabridin, a novel oral compound, with semaglutide serving as the comparator and combination partner. The reported signal is that adding vutiglabridin was associated with overcoming the weight-loss plateau seen with semaglutide alone. As preclinical animal work, it offers mechanistic direction only and does not speak to outcomes in people.
Plain-language abstract
In obese mice, the investigational small molecule vutiglabridin was studied alongside semaglutide and other GLP-1 receptor agonists, where it was associated with continued fat loss past the point where semaglutide's effect leveled off and with less weight regain after semaglutide was stopped.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026